Loading…
← CockpitCompetitor Analysis › 3613.HK Beijing Tong Ren Tang Chinese Medicine Co., Ltd.Open in the cockpit ↗

Beijing Tong Ren Tang Chinese Medicine Co., Ltd.3613.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Momentum neutral 40
Mkt cap
$577M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$688,163
20-day average traded
Fwd P/E
10.2×
forward earnings
ROIC−WACC
+8.4 pp
WACC 6.9%
Hurdle
-18 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · HKDHK$5.43
1D-1.1%
1W-3.5%
1M-6.0%
3M-16.1%
6M-25.5%
YTD-35.8%
1Y-39.4%
ATR %2.2%
52w lowhigh42.8% off high

What Beijing Tong Ren Tang Chinese Medicine does

Employees: 780

Beijing Tong Ren Tang Chinese Medicine at a glance

Size Beijing Tong Ren Tang Chinese Medicine (3613.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $577M, the 714th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.43 on 18 Nov 2026.

Performance Over six months the shares fell 25.5%, against -23.4% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 10th lowest of 21 in its peer set.

Growth Revenue fell 20.8% over the last twelve months (peer median +2.2%); the operating margin is 31.6% (peer median 4.7%).

Valuation It trades at 10.2× forward earnings against a peer median of 11.3× (4th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 8.4 points above its cost of capital (6.9% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 763613.HK 76
Six months, rebased to 100: Beijing Tong Ren Tang Chinese Medicine against the median of its 20 peers (local-currency closes).

Beijing Tong Ren Tang Chinese Medicine financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.35BHK$1.51BHK$1.61BHK$1.52BHK$1.73B
Revenue growth—-6%+6%-12%—
Gross profitHK$847MHK$836MHK$990MHK$976MHK$1.09B
EBITDAHK$526MHK$572MHK$660MHK$699MHK$877M
Net incomeHK$361MHK$397MHK$500MHK$540MHK$646M
Free cash flowHK$632MHK$827M-HK$201MHK$502MHK$519M
Capital expenditureHK$27.4MHK$41.2MHK$43.2MHK$21.9MHK$38.5M
Total debtn/aHK$127MHK$123MHK$132MHK$103M

Quarterly statements and history in the cockpit →

Beijing Tong Ren Tang Chinese Medicine competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-30%-20%-10%-20%0%225647432157603439CGEMALMSENTX300147688356600568IMMX002393600976003850301096ZVRA300233DBV45593613.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Tong Ren Tang Chinese Medicine is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×2157603439688356002393600976003850301096ZVRA45593613.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Tong Ren Tang Chinese Medicine is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%603439300147688356002393600976003850ZVRA30023345593613.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Tong Ren Tang Chinese Medicine is the large dot.

Beijing Tong Ren Tang Chinese Medicine competitors and peer comparison

How Beijing Tong Ren Tang Chinese Medicine compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Tong Ren Tang Chinese Medicine against its 20 peers (data as of 18 Nov 2026)
Measure3613.HKPeer medianRank in peer set
1-month return-6.0%-11.4%7th highest of 21
6-month return-25.5%-23.4%10th lowest of 21
Distance from 52-week high-42.8%-44.0%9th highest of 21
Revenue growth (TTM)-20.8%+2.2%5th lowest of 18
Operating margin31.6%4.7%highest of 17
Forward P/E10.2×11.3×4th cheapest of 10
Growth the price implies (Req g, 7 yrs)-15.4%-3.1%least demanding of 10
Growth delivered (Del g)+2.8%+11.1%3rd lowest of 10
Hurdle (Req g minus delivered)-18.3 pp-9.9 pp3rd least demanding of 10
ROIC minus cost of capital+8.4 pp-4.8 pp2nd highest of 15
EV / EBITDA5.0×7.7×2nd cheapest of 5
Net debt / EBITDA-4.0×1.1×2nd least indebted of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%

Questions

Which companies are Beijing Tong Ren Tang Chinese Medicine's closest peers?
The cockpit's peer set: Abbisko Cayman (2256.HK), Oneness Biotech (4743.TWO), Lepu Biopharma (2157.HK), GuiZhou SanLi Pharmaceutical (603439.SS), Cullinan Therapeutics (CGEM), Alumis (ALMS), Entera Bio (ENTX), Xiangxue Pharmaceutical (300147.SZ).
Is Beijing Tong Ren Tang Chinese Medicine expensive compared with its peers?
On forward p/e it trades at 10.2× against a peer median of 11.3×, 4th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Beijing Tong Ren Tang Chinese Medicine stock performed?
Over six months to 18 Nov 2026 the shares returned -25.5% against -23.4% for the median peer; over one year -39.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.